Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML Clinical Trial

Official title:

A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02193958
• Other study ID #: FF1050101US01
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 2014
• Est. completion date: October 15, 2019

Study information

• Verified date: April 2022
• Source: Fujifilm Pharmaceuticals U.S.A., Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. A total of 20 subjects with MDS/CMML treated at the RP2D are planned, including MDS/CMML subjects treated at the RP2D in Phase 1.

Description:

Subjects will receive FF-10501-01 orally on a twice daily schedule for 14, 21 or 28 days repeated every 28 days (=1 cycle). Disease assessments, including analysis of blood and bone marrow aspirates, will be performed at the end of Cycle 1 and every 2 cycles thereafter. Subjects who demonstrate objective response or stable disease will be allowed to continue therapy with FF-10501-01 until progression of disease, observation of unacceptable adverse events, intercurrent illness or changes in condition that prevent further study participation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: October 15, 2019
• Est. primary completion date: August 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed advanced hematologic malignancies;

Phase 1:

• High-risk MDS/CMML (defined as = 10% peripheral blood or marrow blasts and/or IPSS score = 1.5) and relapsed or refractory to prior therapy

• AML relapsed or refractory to prior therapy, or = 60 years of age and not a candidate for other therapies

Phase 2a:

• MDS/CMML, relapsed from, or refractory to, prior HMA therapy; the latter defined as failure to achieve clinical remission (CR), partial remission (PR) or hematologic improvement (HI) after previous HMA therapy (= 4 cycles of azacitidine or decitabine), or progression during, or toxicity to previous HMA therapy precluding further HMA treatment, and,

• Bone marrow blast count = 10% or peripheral blast count = 5%, or IPSS-R score = 3.5.

• At least 3 weeks beyond the last chemotherapy, targeted anticancer agent, major surgery or experimental treatment and recovered from all acute toxicities (= Grade 1). Hydroxyurea used to control peripheral blast counts is permitted up to Day 7 of treatment on study.

• Adequate performance status: ECOG = 2;

• Adequate renal and hepatic function:

• creatinine = 2.0 mg/dL, or calculated creatinine clearance = 45 mL/min

• total bilirubin = 2 times the upper limit of normal (ULN)

• ALT/AST = 2 times ULN

• Negative serum pregnancy test

• Ability to provide written informed consent

Exclusion Criteria:

• Known history of coronary artery disease, angina, myocardial infarction, congestive heart failure, cardiac arrhythmia or any other type of heart disease present within the last 6 months

• Known family history of hereditary heart disease

• QT interval corrected for rate (QTc) > 450 msec on the electrocardiogram (ECG) obtained at Screening

• Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of anti-microbials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for the care of the patient.

• Presence of active central nervous system (CNS) leukemia. Subjects adequately treated for CNS leukemia documented by 2 consecutive cerebrospinal fluid samples negative for leukemia cells are eligible. Subjects with no history of CNS leukemia will not be required to undergo cerebrospinal fluid sampling for eligibility.

• Known positive for HIV, hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).

• Active infection requiring IV anti-infective usage within the last 7 days prior to study treatment.

• Any other medical intervention or condition which could compromise adherence to study requirements or confound the interpretation of study results.

• Pregnant or breast-feeding.

• Treatment with any investigational product within 28 days prior to Screening.

Related Conditions & MeSH terms

• AML
• CMML
• MDS
• Neoplasms

Intervention

Drug:
• FF-10501-01
FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Locations

Country	Name	City	State
United States	Cleveland Clinic at Taussig Cancer Center	Cleveland	Ohio
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Fujifilm Pharmaceuticals U.S.A., Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessed by adverse events	Safety and tolerability assessed by adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicity (DLT), dose reductions, delays or withdrawals due to toxicity	12 months
Secondary	Determination of overall response rates.	Response criteria by IWG Response Criteria for AML (AML subjects) or IWG Response Criteria for MDS (MDS and CMML subjects)	Responses and survival assessed at end of Cycle 1 and every 2 cycles thereafter through 6 months following last dose of study drug. Each cycle is 28 days in length.
Secondary	Evaluate the pharmacokinetic profile of FF-10501-01 and its metabolite.	Cmax, Tmax, Half-life, AUC, Clearance, Volume of Distribution	Evaluated at three timepoints: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1. Each cycle is 28 days in length.
Secondary	Changes from baseline in xanthosine monophosphate (XMP) as a pharmacodynamic marker.	Xanthosine monophosphate (XMP)	Evaluated at three timepoints: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1. Each cycle is 28 days in length.
Secondary	Evaluate the proportion of subjects who achieve hematologic improvement in peripheral blood or bone marrow blast count.	Response Criteria by IWG Response Criteria for AML (AML subjects) or IWG Response Criteria for MDS (MDS and CMML subjects).	Responses and survival assessed at the end of Cycle 1 and every 2 cycles thereafter through 6 months following last dose of study drug. Each cycle is 28 days in length.
Secondary	Evaluate progression-free survival (PFS).	Response Criteria by IWG Response Criteria for AML (AML subjects) or IWG Response Criteria for MDS (MDS and CMML subjects).	Responses and survival assessed at end of Cycle 1 and every 2 cycles thereafter through 6 months following last dose of study drug. Each cycle is 28 days in length.
Secondary	Evaluate overall survival (OS).	Response criteria by IWG Response Criteria for AML (AML subjects) or IWG Response Criteria for MDS (MDS and CMML subjects).	Responses and survival assessed at end of Cycle 1 and every 2 cycles thereafter through 6 months following last dose of study drug. Each cycle is 28 days in length.